<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05087953</url>
  </required_header>
  <id_info>
    <org_study_id>SDC 5045/20/074</org_study_id>
    <nct_id>NCT05087953</nct_id>
  </id_info>
  <brief_title>Autonomic Evaluation of Patients With Hereditary Amyloidotic Cardiomyopathy: Hereditary Amyloidotic Heart Disease</brief_title>
  <official_title>Comparative Analysis of the Autonomic Profile Between Patients With Hereditary Amyloidotic Cardiomyopathy Caused by Transthyretin and Patients With Transthyretin Gene Mutation, Without Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fleury</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transthyretin amyloidosis exhibits a variety of possible phenotypes, the hereditary&#xD;
      neurological form being the most commonly found and studied (familial amyloidotic&#xD;
      polyneuropathy or FAP), which can present from oligosymptomatic patients to patients with&#xD;
      peripheral sensorimotor polyneuropathy of varying degrees and dysautonomia.&#xD;
&#xD;
      Although a specific mutation usually causes a specific phenotype, that is, with a&#xD;
      predominantly cardiac or preferential neurological profile, with the increase in the number&#xD;
      of diagnosed cases, an overlapping of clinical presentations has been observed.&#xD;
&#xD;
      The assessment of the autonomic profile in individuals with familial amyloidotic&#xD;
      cardiomyopathy (FAC) has not been well studied, and it is not known whether patients with an&#xD;
      exclusively cardiac profile of the disease may present dysautonomia or whether even mutation&#xD;
      carriers without cardiac involvement may exhibit it.&#xD;
&#xD;
      In this study, the autonomic profiles of patients with familial amyloidotic heart disease&#xD;
      will be compared with the profiles of patients who have mutations but without established&#xD;
      heart disease and healthy individuals (control group).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Autonomic response profile of patients with FAC.</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the autonomic profile by analyzing the heart rate variability on 24 hours Holter monitoring, the patterns of chronotropic and pressure response and the valsalva maneuver in the tilt table test of patients with FAC, with individuals with mutations of the transthyretin gene without FAC and in healthy individuals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between dysautonomia and electrophysiological cardiac disturbances.</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the relationship of dysautonomia with atrioventricular, intraventricular, interventricular conduction disturbances, presence of late potentials in the high-resolution electrocardiogram and occurrence of supraventricular and ventricular arrhythmias on Holter monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between dysautonomy and structural cardiac alterations.</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the relationship of dysautonomia changes with cardiac structural changes assessed by strain echocardiography.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Autonomic Nervous System Disease</condition>
  <condition>Amyloid Neuropathies</condition>
  <arm_group>
    <arm_group_label>FAC group</arm_group_label>
    <description>Patients with familial amyloidotic cardiomyopathy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-FAC group</arm_group_label>
    <description>Patients with transthyretin gene mutations who do not have FAC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healthy subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Head-Up Tilt table test</intervention_name>
    <description>Autonomic response assessment in the orthostatic head up tilt test.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>FAC group</arm_group_label>
    <arm_group_label>Non-FAC group</arm_group_label>
    <other_name>Tilt-test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Heart Rate Variability</intervention_name>
    <description>Assessment of heart rate variability on 24-hour Holter monitoring..</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>FAC group</arm_group_label>
    <arm_group_label>Non-FAC group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Ischemic or hemorrhagic stroke within the last 6 months;&#xD;
&#xD;
          -  History of ischemic heart disease;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Severe lung disease;&#xD;
&#xD;
          -  Resistant systemic arterial hypertension;&#xD;
&#xD;
          -  Diabetics;&#xD;
&#xD;
          -  Presence of pacemaker or CDI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  FAC group: patients with familial familial amyloidotic cardiomyopathy (FAC).&#xD;
&#xD;
          -  Non-FAC group: patients with transthyretin gene mutations who do not have FAC.&#xD;
&#xD;
          -  Control group: healthy, asymptomatic individuals without comorbidities and without&#xD;
             transthyretin gene mutations.&#xD;
&#xD;
          -  Agreement and signing the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Bruno VK Bueno, MD</last_name>
    <phone>+55(11)98187-7226</phone>
    <email>vazkerges@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto do Coração - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sao Paulo Medical School - The Heart Institute</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fabio Fernandes</name>
      <address>
        <city>São Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010 Jul;7(7):398-408. doi: 10.1038/nrcardio.2010.67. Epub 2010 May 18. Review.</citation>
    <PMID>20479782</PMID>
  </reference>
  <reference>
    <citation>Cruz MW. Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil. Amyloid. 2012 Jun;19 Suppl 1:65-7. doi: 10.3109/13506129.2012.673183. Epub 2012 Apr 12.</citation>
    <PMID>22494049</PMID>
  </reference>
  <reference>
    <citation>Queiroz MC, Pedrosa RC, Berensztejn AC, Pereira Bde B, Nascimento EM, Duarte MM, Pereira-Junior PP, Cruz MW. Frequency of Cardiovascular Involvement in Familial Amyloidotic Polyneuropathy in Brazilian Patients. Arq Bras Cardiol. 2015 Nov;105(5):503-9. doi: 10.5935/abc.20150112. Epub 2015 Sep 8. English, Portuguese.</citation>
    <PMID>26351985</PMID>
  </reference>
  <reference>
    <citation>Cruz MW, Foguel D, Berensztejn AC, Pedrosa RC, Mundayat R, Ong ML; THAOS Investigators. The demographic, genetic, and clinical characteristics of Brazilian subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey. Amyloid. 2017 Mar;24(sup1):103-104. doi: 10.1080/13506129.2017.1291423.</citation>
    <PMID>28434317</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

